Rationale and design of the Affordability and Real-world Antiplatelet Treatment Effectiveness after Myocardial Infarction Study (ARTEMIS): A multicenter, cluster-randomized trial of P2Y12 receptor inhibitor copayment reduction after myocardial infarction.
暂无分享,去创建一个
K. Anstrom | C. Cannon | T. Henry | E. Peterson | G. Fonarow | N. Choudhry | D. Cohen | Tracy Y. Wang | Durgesh D. Bhandary | Naeem D. Khan | L. Davidson-Ray | Jacob A. Doll | D. Cohen | D. Cohen
[1] Baris Gencer,et al. ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation , 2011 .
[2] T. Henry,et al. Persistence with secondary prevention medications after acute myocardial infarction: Insights from the TRANSLATE-ACS study. , 2015, American heart journal.
[3] H. Gurm,et al. Contemporary Use of Ticagrelor in Interventional Practice (from Blue Cross Blue Shield of Michigan Cardiovascular Consortium). , 2015, The American journal of cardiology.
[4] K. Anstrom,et al. Cluster-Randomized Clinical Trial Examining the Impact of Platelet Function Testing on Practice: The Treatment With Adenosine Diphosphate Receptor Inhibitors: Longitudinal Assessment of Treatment Patterns and Events After Acute Coronary Syndrome Prospective Open Label Antiplatelet Therapy Study , 2015, Circulation. Cardiovascular interventions.
[5] L. Boulanger,et al. Moving branded statins to lowest copay tier improves patient adherence. , 2015, Journal of managed care pharmacy : JMCP.
[6] A. Jaffe,et al. A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines , 2015 .
[7] K. Anstrom,et al. Abstract 16776: Can We Rely on Patients to Report Rehospitalizations After Acute Myocardial Infarction? Implications for the Design of Future Practical Clinical Studies , 2014 .
[8] E. Peterson,et al. Persistence of evidence-based medication use after discharge from academic versus nonacademic hospitals among patients with non-ST-segment elevation myocardial infarction. , 2014, The American journal of cardiology.
[9] F. Gaita,et al. Discontinuation of dual antiplatelet therapy over 12 months after acute coronary syndromes increases risk for adverse events in patients treated with percutaneous coronary intervention: systematic review and meta-analysis. , 2014, Journal of interventional cardiology.
[10] T. Brennan,et al. Eliminating medication copayments reduces disparities in cardiovascular care. , 2014, Health affairs.
[11] Eric D. Peterson,et al. Early Clopidogrel Versus Prasugrel Use Among Contemporary STEMI and NSTEMI Patients in the US: Insights From the National Cardiovascular Data Registry , 2014, Journal of the American Heart Association.
[12] Braden J. Manns,et al. Association between Drug Insurance Cost Sharing Strategies and Outcomes in Patients with Chronic Diseases: A Systematic Review , 2014, PloS one.
[13] R. Haynes,et al. Interventions for enhancing medication adherence. , 2008, The Cochrane database of systematic reviews.
[14] T. Brennan,et al. Untangling the relationship between medication adherence and post-myocardial infarction outcomes: medication adherence and clinical outcomes. , 2014, American heart journal.
[15] Antonio Colombo,et al. Cessation of dual antiplatelet treatment and cardiac events after percutaneous coronary intervention (PARIS): 2 year results from a prospective observational study , 2013, The Lancet.
[16] Claire Buckley,et al. The Effect of Copayments for Prescriptions on Adherence to Prescription Medicines in Publicly Insured Populations; A Systematic Review and Meta-Analysis , 2013, PloS one.
[17] H. Gurm,et al. Contemporary Use of Prasugrel in Clinical Practice: Insights From the Blue Cross Blue Shield of Michigan Cardiovascular Consortium , 2013, Circulation. Cardiovascular quality and outcomes.
[18] Jane A. Linderbaum,et al. 2013 ACCF/AHA guideline for the management of ST-elevation myocardial infarction: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. , 2013, Journal of the American College of Cardiology.
[19] G. Stone,et al. Stent thrombosis after primary angioplasty for STEMI in relation to non-adherence to dual antiplatelet therapy over time: results of the HORIZONS-AMI trial. , 2013, EuroIntervention : journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology.
[20] T. Brennan,et al. Comparative cost-effectiveness of interventions to improve medication adherence after myocardial infarction. , 2012, Health services research.
[21] Katie Merrell,et al. In Medicare Part D plans, low or zero copays and other features to encourage the use of generic statins work, could save billions. , 2012, Health affairs.
[22] K. Anstrom,et al. Patient-focused intervention to improve long-term adherence to evidence-based medications: a randomized trial. , 2012, American heart journal.
[23] Helmut Baumgartner,et al. ESC / EACTS Guidelines on myocardial revascularization , 2014 .
[24] Lonny Reisman,et al. Full coverage for preventive medications after myocardial infarction. , 2011, The New England journal of medicine.
[25] K. Anstrom,et al. Treatment with adenosine diphosphate receptor inhibitors-longitudinal assessment of treatment patterns and events after acute coronary syndrome (TRANSLATE-ACS) study design: expanding the paradigm of longitudinal observational research. , 2011, American heart journal.
[26] Claes Held,et al. Ticagrelor versus clopidogrel in patients with acute coronary syndromes. , 2009, The New England journal of medicine.
[27] R. F. Kelly,et al. Association of medical noncompliance and long-term adverse outcomes, after myocardial infarction in a minority and uninsured population. , 2009, Translational research : the journal of laboratory and clinical medicine.
[28] W. Doucette,et al. Effect of cost sharing on prescription drug use by Medicare beneficiaries prior to the Medicare Drug Benefit and potential adverse selection in the benefit. , 2009, Journal of the American Pharmacists Association : JAPhA.
[29] A. Fendrick,et al. Effects of Increased Patient Cost Sharing on Socioeconomic Disparities in Health Care , 2008, Journal of General Internal Medicine.
[30] A. Oxman,et al. Pharmaceutical policies: effects of cap and co-payment on rational drug use. , 2008, The Cochrane database of systematic reviews.
[31] E. Antman,et al. Prasugrel versus clopidogrel in patients with acute coronary syndromes. , 2007, The New England journal of medicine.
[32] Dana P Goldman,et al. Prescription drug cost sharing: associations with medication and medical utilization and spending and health. , 2007, JAMA.
[33] J. Gurwitz,et al. Patients At-Risk for Cost-Related Medication Nonadherence: A Review of the Literature , 2007, Journal of General Internal Medicine.
[34] D. Ashby,et al. Sample size for cluster randomized trials: effect of coefficient of variation of cluster size and analysis method. , 2006, International journal of epidemiology.
[35] R. Goetzel,et al. The effects of prescription drug cost sharing: a review of the evidence. , 2005, The American journal of managed care.
[36] Maurice Sokolow,et al. American Heart Journal , 2001 .
[37] W C Hsiao,et al. Results and policy implications of the resource-based relative-value study. , 1988, The New England journal of medicine.